A U.S. Patent for "Efficient Selectivity of Recombinant Proteins" was  awarded to Regeneron  on October 29th, 2019 . The present invention provides a new expression system comprising a mammalian selectable marker that promotes desirable p

Amgen is stopping the vast majority of its neuroscience research, as company executives concluded their efforts are unlikely to yield long-term success, according to a statement by R&D head David Reese. This decision and associated reorganizat

A U.S. Patent for "Robust Antibody Purification" was awarded to Merck on October 29th, 2019. The present invention is a method for the separation of host cell proteins, antibody fragments and low molecular weig

Research conducted by CPhI Worldwide ranks Germany as Europe's preeminent pharma industry. The data was drawn from the CPhI Annual Report and includes opinions from over 350 international pharma companies. The 'CPhI Pharma Index' is the only annua

A new type of micromotor -- powered by ultrasound and steered by magnets -- can move around individual cells and microscopic particles in crowded environments without damaging them. In one demonstration, a micromotor pushed around silica particles

Nuvation Bio peeked out from stealth mode this week to reveal $275 million in financing and an executive team stacked with biotech veterans. The cancer drug developer is led by founder, president, and CEO David Hung, the former chief executive who

GlaxoSmithKline said this week that it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection. The antibiotic, gepotidacin, is the first o

Teesside University in the United Kingdom has officially opened its $28 million National Horizons Centre, which it believes will catalyze talent development and increase engagement between research, teaching and industry. The university already ha

Bluebird bio has secured from European health regulators clearance of new manufacturing specifications for its recently approved gene therapy Zynteglo. Alert readers will recall that Back in June, Bluebird won a conditional approval for the Europe

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported this week.

Alkermes this week announced that it will lay off about 160 employees, curtail future hiring and cut spending as it starts a corporate restructuring designed to stem losses. The Irish biopharma expects to complete most of the job cuts by the end o

Novartis' experimental asthma treatment fevipiprant failed to improve lung function in a pair of Phase 3 studies of patients with moderate asthma, the Swiss pharma disclosed Tuesday in its third quarter earnings report. Company executives downplay

Wednesday, October 23rd, 2019

With the expansion of single-use systems in all process steps of commercial manufacturing, integrity failure can significantly affect drug safety, availabili